Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Drug-eluting stent

A technology for eluting stents and drugs, used in stents, drug combinations, drug delivery, etc., can solve problems such as complex processes, and achieve the effects of improving restenosis, inhibiting intimal thickening, and high coating strength

Active Publication Date: 2017-08-29
JIMRO
View PDF25 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For example, patent reference 20 discloses the experiment of converting a biocompatible particle into its nanoparticle and then coating the scaffold with the nanoparticle and cilostazol particles by a charge-based method, but the process of preparing it is very complicated

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug-eluting stent
  • Drug-eluting stent
  • Drug-eluting stent

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0098] A cobalt-chromium alloy as the base member 2 is coated with a mixture of cilostazol and one of the polymers listed above (e), (j) and (p) by ultrasonic spraying, wherein cilostazol and The mixing ratio of the polymers was varied as shown in Table 2, and the strength of each coating was evaluated. The results are shown in Table 2. In the table, the symbol "○" indicates that the intensity is very high, the symbol "Δ" indicates that the intensity is high, and the symbol "×" indicates that the intensity is low.

[0099] The results show that when the mixing ratio (D / P ratio) of cilostazol and polymer is 6:4 or lower, that is, when the amount of cilostazol is smaller than this ratio, the strength is high, and particularly, when the With a ratio of 5:5, the intensity is high enough. However, when the D / P ratio is less than 4:6, it is presumed that the drug effect of cilostazol for drug-eluting stents may be reduced. Therefore, the D / P ratio is preferably 4:6 or higher.

...

Embodiment 2

[0103] A cobalt-chromium alloy as the base member 2 was coated with a coating agent prepared by mixing cilostazol and one of the 17 kinds of polymers (a) to (q) listed in Table 1 by ultrasonic spraying. The mixing ratio of cilostazol and each polymer is 5:5.

[0104] The appearance of each prepared stent was observed in terms of coating work. On external observation, in the coated stent there is no evidence of image 3 The meshes in the close together or without are shown in the Figure 4 A coated stent with uneven coating and a surface that was flat and smooth, not like orange peel, was rated as "good". The results are shown in Figure 5 middle. exist Figure 5 In , the axis of coordinates represents the molecular weight of each polymer mixed with cilostazol, and the axis of abscissa represents the dissolution rate of the coating agent. displayed on Figure 5 (a) to (q), which are the 17 polymers listed in Table 1, show the relationship of the two factors by their posi...

Embodiment 3

[0107] Scaffolds were prepared in a similar manner to Example 2 using the above polymers (e), (h), (j), (m), (p) and (q). As explained below, each prepared stent was placed in the iliac vessel of a rabbit, and the effect of each stent on inhibiting intimal thickening was evaluated.

[0108] First, the rabbit's neck was cut open, and the right carotid artery was taken out, and an introducer was connected thereto. The guide wire of the balloon catheter is inserted from the introducer and moved under X-ray fluoroscopy to the distal part of the iliac artery to be treated. And then, an angiographic catheter is inserted along the guide wire, and angiography is performed at the treated site of the iliac artery. After performing angiography at the treatment site, a balloon catheter with a test stent was inserted into the treatment site under X-ray fluoroscopy along the guide wire of the balloon catheter. The test stent (where the stent diameter is 2.75 mm when the standard diameter ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a drug-eluting stent that includes coating the surface of a stent body comprising a metal or polymer material by a mixture of cilostazol and a bioabsorbable polymer, wherein the molecular weight of the bioabsorbable polymer is from 40,000 to 600,000.

Description

technical field [0001] The present invention may relate to cilostazol-coated stents and methods of making the same. Background technique [0002] Current medical progress brings about remarkable developments in the treatment / prevention of various diseases such as infectious diseases, but patients with arteriosclerotic diseases or the like caused by poor lifestyles tend to increase. In particular, patients with arteriosclerotic diseases such as myocardial infarction, angina pectoris, stroke, and peripheral vascular disease are increasingly increasing in Japan, which is associated with Westernization of lifestyle and aging. As a method for safely treating such arteriosclerotic diseases, percutaneous transluminal angioplasty (hereinafter referred to as "PTA"), which is an angioplasty to surgically expand a narrowed or blocked portion in a blood vessel, such as This is typical of percutaneous transluminal coronary angioplasty in the coronary arteries. PTA, which operates on na...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61F2/82A61L31/00
CPCA61F2/82A61L31/10A61L31/148A61L31/16A61K31/4709A61L2300/42A61L2300/434A61F2250/0067A61P43/00C08L67/04A61K47/6957A61K9/0024A61L31/022A61F2240/001A61F2/90A61L31/14
Inventor 真锅松也
Owner JIMRO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com